Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2200058265Phase 4Not yet recruiting
Phase 4, open-label, single-arm trial of pyrotinib in Nonhematologic neoplasms and brain metastases, sponsored by Beijing Tiantan Hospital. Primary endpoint: Progression-Free Survival. Planned start Mar 2022; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2200058265.